暂无数据
代码股票名称
最新价涨跌额涨跌幅成交量成交额今开昨收最高最低总市值流通市值总股本流通股本5日涨跌幅10日涨跌幅20日涨跌幅60日涨跌幅120日涨跌幅250日涨跌幅年初至今涨跌幅股息率TTM换手率市盈率TTM市盈率(静)振幅所属行业
美股期权个股详情
TXG240517C25000
- 0.50
- -0.30-37.50%
延时15分钟行情收盘价 05/17 15:59 (美东)
0.50最高价0.50最低价
0.50今开0.80昨收10张成交量62张未平仓合约数25.00行权价500.00成交额613.06%隐含波动率1.96%溢价2024/05/17到期日0.01内在价值100合约乘数0天距到期日0.49时间价值100合约规模美式期权类型0.5131Delta0.3213Gamma50.02杠杆倍数-10.6211Theta0.0000Rho25.67有效杠杆0.0008Vega
分时
- 5日
- 日K
新闻
在德国专利法院的裁决中，10x Genomics股票下滑
快讯 | 德国联邦专利法院宣布德国第 2794928b1 号欧洲专利无效
德国联邦专利法院宣布10x Genomics主张的专利无效，为现为布鲁克旗下的NanoString带来法律胜利，将寻求终止影响CosmX SMI产品在德国销售的禁令
现在是布鲁克旗下的NanoString将立即寻求终止影响CosmX SMI产品在德国销售的禁令。布鲁克公司（纳斯达克股票代码：BRKR）今天宣布，德国联邦
快讯 | Bruker Corp-德国联邦专利法院宣布10X Genomics主张的专利无效
快讯 | 10X Genomics Inc：斯蒂芬斯将目标价格从62美元下调至45美元
分析师对这些医疗保健股的看法不一：Bausch + Lomb Corporation（BLCO）、10x Genomics（TXG）和LivaNova（LIVN）
评论
$10x Genomics(TXG.US$ no idea what is this even but the chart is so ugly & i love buying ugly charts
1
Analysts predict 10x Genomics will reach cashflow breakeven before depleting its cash reserves. The company appears well-positioned to fund its growth, with options to raise more capital through share issuance or debt.
1
James Wilbur's share sale prompts doubts about insiders’ view of stock's worth. No insider buying in past year may hint at uncertainty in company's future, despite high insider ownership suggesting management's awareness of shareholders' interests.
$10x Genomics(TXG.US$ why the jump up today in price action?
阅读更多